These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 21792316)

  • 1. Current therapeutic strategies for invasive and metastatic bladder cancer.
    Vishnu P; Mathew J; Tan WW
    Onco Targets Ther; 2011; 4():97-113. PubMed ID: 21792316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in the treatment of bladder cancer.
    Kaufman DS
    Ann Oncol; 2006 May; 17 Suppl 5():v106-12. PubMed ID: 16807436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bladder cancer. Advances in laboratory innovations and clinical management, with emphasis on innovations allowing bladder-sparing approaches for patients with invasive tumors.
    Shipley WU; Prout GR; Kaufman DS
    Cancer; 1990 Feb; 65(3 Suppl):675-83. PubMed ID: 2405994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.
    Pietzak EJ; Zabor EC; Bagrodia A; Armenia J; Hu W; Zehir A; Funt S; Audenet F; Barron D; Maamouri N; Li Q; Teo MY; Arcila ME; Berger MF; Schultz N; Dalbagni G; Herr HW; Bajorin DF; Rosenberg JE; Al-Ahmadie H; Bochner BH; Solit DB; Iyer G
    Eur Urol; 2019 Feb; 75(2):231-239. PubMed ID: 30290956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patterns of failure following surgical resection for malignant pleural mesothelioma.
    Jänne PA; Baldini EH
    Thorac Surg Clin; 2004 Nov; 14(4):567-73. PubMed ID: 15559064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines.
    Witjes JA; Bruins HM; Cathomas R; Compérat EM; Cowan NC; Gakis G; Hernández V; Linares Espinós E; Lorch A; Neuzillet Y; Rouanne M; Thalmann GN; Veskimäe E; Ribal MJ; van der Heijden AG
    Eur Urol; 2021 Jan; 79(1):82-104. PubMed ID: 32360052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Biomarkers of Response to Neoadjuvant Therapy in Muscle Invasive Bladder Cancer.
    Nikkola J; Black P
    Methods Mol Biol; 2023; 2684():229-247. PubMed ID: 37410238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?
    Osanto S; Álvarez Gómez de Segura C
    Arch Esp Urol; 2020 Dec; 73(10):971-985. PubMed ID: 33269716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving Systemic Chemotherapy for Bladder Cancer.
    Rose TL; Milowsky MI
    Curr Oncol Rep; 2016 May; 18(5):27. PubMed ID: 26984414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
    Sternberg CN; Donat SM; Bellmunt J; Millikan RE; Stadler W; De Mulder P; Sherif A; von der Maase H; Tsukamoto T; Soloway MS
    Urology; 2007 Jan; 69(1 Suppl):62-79. PubMed ID: 17280909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining surgery and chemotherapy for invasive bladder cancer: current and future directions.
    Amiel GE; Lerner SP
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):281-91. PubMed ID: 16445380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.
    Kim KH; Lee HW; Ha HK; Seo HK
    Investig Clin Urol; 2023 May; 64(3):202-218. PubMed ID: 37341001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments.
    Roviello G; Catalano M; Santi R; Santoni M; Galli IC; Amorosi A; Polom W; De Giorgi U; Nesi G
    Front Oncol; 2022; 12():912699. PubMed ID: 35936721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The efficacy of radiotherapy based combined therapy for unresectable locally invasive bladder cancer and its associated factors analysis].
    Zhong SJ; Gao JJ; Tang P; Liu YP; Wang SL; Fang H; Qiu JP; Song YW; Chen B; Qi SN; Tang Y; Lu NN; Jing H; Zhai YR; Zhou AP; Bi XG; Ma JH; Li CL; Zhang Y; Shou JZ; Xing NZ; Li YX
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):175-181. PubMed ID: 36781240
    [No Abstract]   [Full Text] [Related]  

  • 17. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
    Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
    Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer.
    Esteban-Villarrubia J; Torres-Jiménez J; Bueno-Bravo C; García-Mondaray R; Subiela JD; Gajate P
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy.
    Fung CY; Shipley WU; Young RH; Griffin PP; Convery KM; Kaufman DS; Althausen AF; Heney NM; Prout GR
    J Clin Oncol; 1991 Sep; 9(9):1533-42. PubMed ID: 1875217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.